Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
Investigational once-weekly GLP-1 and amylin receptor agonist achieves up to 14.6% weight loss and significant blood sugar reductions
The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
Novel fluorescent nanosensor enables real-time detection of indole-3-propionic acid (IPA), paving the way for faster gut health screening, point-of-care diagnostics, and wearable monitoring devices
Libre Duo devices become the first glucose-ketone monitors approved for diabetes care, offering real-time alerts for diabetic ketoacidosis risk
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
